Close Menu

In Just One Dose

MIT's Tech Review reports on Alnylam's RNAi-based drug that, with one dose, lowers cholesterol by up to 60 percent in rodents and monkeys. The drug targets PCSK9, an enzyme that had been shown to affect LDL levels and people's risk of heart disease. The RNAi drug was bundled into lipid-based nanoparticles to be transported to the liver once injected. This drug, says the article, could be used in conjunction with statins to get LDL levels even lower.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.

St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.

St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.

In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.